News

4SC: overall survival benefit for resminostat in first-line liver cancer study subgroup

Details

Data from a randomized, multi-center, 170 patient Phase II study with resminostat as first-line treatment of advanced liver cancer presented at 2017 Gastrointestinal Cancers Symposium shows substantial increase in overall survival 

immatics and Amgen sign $1B deal

Details

Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies 

Themis vector technology featured in quest for Zika vaccine by Top EU-groups

Details

Leading European research groups pool their expertise for the fast development of an effective and affordable vaccine against the Zika virus.  

  1. AYOXXA appoints permanent CEO
  2. invendo medical announces CE mark
  3. Chiesi Group acquires Atopix
  4. Wellington invests in Uromems
© Wellington Partners, 2018.